Published in Europace on July 26, 2011
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST) | NCT01288352
Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc (2012) 1.98
Lone atrial fibrillation: does it exist? J Am Coll Cardiol (2014) 1.21
Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J (2013) 1.17
B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace (2014) 0.99
Clinical implications of recent trials on anticoagulation in patients with atrial fibrillation. Res Cardiovasc Med (2012) 0.98
Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making? Circulation (2012) 0.97
Increased risk of atrial fibrillation among elderly Norwegian men with a history of long-term endurance sport practice. Scand J Med Sci Sports (2013) 0.86
Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf (2014) 0.85
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Neth Heart J (2013) 0.84
Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J (2016) 0.84
Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovasc Diabetol (2015) 0.81
Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. Arq Bras Cardiol (2015) 0.81
The Relationship between Obstructive Sleep Apnea and Atrial Fibrillation: A Complex Interplay. Pulm Med (2013) 0.80
Score for atrial fibrillation detection in acute stroke and transient ischemic attack patients in a Brazilian population: the acute stroke atrial fibrillation scoring system. Clinics (Sao Paulo) (2014) 0.79
Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc (2014) 0.78
Personalized medicine and atrial fibrillation: will it ever happen? BMC Med (2012) 0.76
Auscultatory versus oscillometric blood pressure measurement in patients with atrial fibrillation and arterial hypertension. BMC Cardiovasc Disord (2017) 0.75
A Non-Surgeon's Guide to Surgical Management of Atrial Fibrillation. J Surg (Northborough) (2013) 0.75
Catheter ablation in patients with persistent atrial fibrillation. Eur Heart J (2016) 0.75
Cluster Individuals Based on Phenotype and Determine the Risk for Atrial Fibrillation in the PREVEND and Framingham Heart Study Populations. PLoS One (2016) 0.75
Atrial high-rate episodes and stroke prevention. Europace (2017) 0.75
Atrial fibrillation and gastroesophageal reflux disease: From the cardiologist perspective. World J Gastroenterol (2015) 0.75
Distinct risk factors of atrial fibrillation in patients with and without coronary artery disease: a cross-sectional analysis of the BOREAS-CAG Registry data. Open Heart (2017) 0.75
Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives. Cardiovasc Diagn Ther (2015) 0.75
Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women. Heart (2017) 0.75
Predisposing factors for atrial fibrillation in the elderly. J Geriatr Cardiol (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med (1998) 23.22
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 11.63
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med (1982) 8.62
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Incidence of and risk factors for atrial fibrillation in older adults. Circulation (1997) 8.18
Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature (2007) 8.03
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med (1999) 7.74
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med (1995) 6.49
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA (2009) 5.22
A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA (2004) 5.20
Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation (1997) 5.16
Inflammation as a risk factor for atrial fibrillation. Circulation (2003) 4.95
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med (1994) 4.74
Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J (2004) 4.71
Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ (2001) 4.66
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation (2009) 4.33
Short QT Syndrome: a familial cause of sudden death. Circulation (2003) 4.23
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med (2010) 4.16
Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol (2011) 4.12
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol (1994) 4.08
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol (2006) 3.96
Association of atrial fibrillation and obstructive sleep apnea. Circulation (2004) 3.81
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation (2010) 3.72
New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J Am Coll Cardiol (2008) 3.67
Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation (2007) 3.57
Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation (2003) 3.57
Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res (2007) 3.51
Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation (2009) 3.50
Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol (2004) 3.50
Thyroid status, cardiovascular risk, and mortality in older adults. JAMA (2006) 3.50
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke (2007) 3.33
Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med (2000) 3.23
Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol (2003) 3.20
Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J Cardiovasc Electrophysiol (2010) 3.18
Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol (2007) 2.99
The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol (2010) 2.96
High-density mapping of electrically induced atrial fibrillation in humans. Circulation (1994) 2.94
Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation (2008) 2.85
Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med (2005) 2.84
Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev (2011) 2.78
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol (2008) 2.74
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65
Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J (2006) 2.59
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol (2009) 2.59
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology (2000) 2.59
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation (2010) 2.57
PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet (2011) 2.56
Left atrial strain measured by two-dimensional speckle tracking represents a new tool to evaluate left atrial function. J Am Soc Echocardiogr (2010) 2.56
Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol (2006) 2.55
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace (2009) 2.52
Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol (2010) 2.51
Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol (2002) 2.50
Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology (2009) 2.47
Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. Eur Heart J (2005) 2.45
Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med (2006) 2.45
Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation (1997) 2.41
Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol (2007) 2.41
Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol (2005) 2.39
Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology (2010) 2.39
Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging (2010) 2.36
Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation (2010) 2.32
Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace (2008) 2.32
Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm (2006) 2.30
Birth weight is a significant risk factor for incident atrial fibrillation. Circulation (2010) 2.30
Mechanisms of wave fractionation at boundaries of high-frequency excitation in the posterior left atrium of the isolated sheep heart during atrial fibrillation. Circulation (2006) 2.30
Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation (1997) 2.29
Epicardial mapping of chronic atrial fibrillation in patients: preliminary observations. Circulation (2004) 2.29
Familial aggregation of atrial fibrillation in Iceland. Eur Heart J (2006) 2.27
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Universal definition of myocardial infarction. Circulation (2007) 11.69
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. N Engl J Med (2015) 8.61
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J (2007) 7.34
Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 6.73
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound. J Am Coll Cardiol (2005) 5.99
An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med (2010) 5.32
Defibrillator implantation early after myocardial infarction. N Engl J Med (2009) 5.25
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res (2002) 4.86
Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med (2005) 4.80
Cardiovascular events during World Cup soccer. N Engl J Med (2008) 4.74
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) 4.64
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation (2010) 4.60
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15
Resting heart rate in cardiovascular disease. J Am Coll Cardiol (2007) 4.14
Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Drug induced QT prolongation and torsades de pointes. Heart (2003) 3.97
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
A trial of an impedance threshold device in out-of-hospital cardiac arrest. N Engl J Med (2011) 3.76
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Mapping and ablation of idiopathic ventricular fibrillation. Circulation (2002) 3.69